COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,833 Articles (22,553 medRxiv, 8,280 bioRxiv)

Most recent first Previous |  Page 792: Articles 7911-7920  | Next

Hippo Signaling Pathway Activation during SARS-CoV-2 Infection Contributes to Host Antiviral Response
Garcia, G., Wang, Y., Irudayam, J. I., Jeyachandran, A. V., Cario, S. C., Sen, C., Li, S., Li, Y., Kumar, A., Nielsen-Saines, K., French, S. W., Shah, P. S., Morizono, K., Gomperts, B., Deb, A., Ramaiah, A., Arumugaswami, V.
10.1101/2022.04.07.487520 — Posted: 2022-04-08
The Delta variant SARS-CoV-2 spike protein uniquely promotes aggregation of pseudotyped viral particles
Petersen, J. D., Lu, J., Fitzgerald, W., Zhou, F., Blank, P. S., Matthies, D., Zimmerberg, J.
10.1101/2022.04.07.487415 — Posted: 2022-04-08
Plant-produced RBD and cocktail-based vaccine candidates are highly effective against SARS-CoV-2, independently of its emerging variants
Mammedov, T., Yuksel, D., Grbzaslan, I., Ilgn, M., Gulec, B., Mammadova, G., Ozdarendeli, A., Islam Pavel, S. T., Yetiskin, H., Kaplan, B., Uygut, M. A., Hasanova, G.
10.1101/2022.04.07.487347 — Posted: 2022-04-08
Built environment's impact on COVID-19 transmission and mental health revealed by COVID-19 Participant Experience data from the All of Us Research Program
Luo, W., Baldwin, E., Jiang, A. Y., Li, S., Yang, B., Li, H.
10.1101/2022.04.05.22273358 — Posted: 2022-04-07
Risk factors for severe COVID-19 in hospitalized children in Canada: A national prospective study from March 2020--May 2021
Farrar, D. S., Drouin, O., Moore Hepburn, C., Baerg, K., Chan, K., Cyr, C., Donner, E. J., Embree, J. E., Farrell, C., Forgie, S., Giroux, R., Kang, K. T., King, M., Laffin Thibodeau, M., Orkin, J., Ouldali, N., Papenburg, J., Pound, C. M., Price, V. E., Proulx-Gauthier, J.-P., Purewal, R., Ricci, C., Sadarangani, M., Salvadori, M. I., Thibeault, R., Top, K. A., Viel Theriault, I., Kakkar, F., Morris, S. K.
10.1101/2022.04.06.22273409 — Posted: 2022-04-07
Early SARS-CoV-2 reinfections within 60 days highlight the need to consider antigenic variations together with duration of immunity in defining retesting policies
Nevejan, L., Cuypers, L., Laenen, L., Van Loo, L., Vermeulen, F., Wollants, E., Van Hecke, I., Desmet, S., Lagrou, K., Maes, P., Andre, E.
10.1101/2022.04.04.22273172 — Posted: 2022-04-07
Combined Infection Control Interventions Protect the Essential Workforce from Occupationally-Acquired SARS-CoV-2 during Produce Production, Harvesting and Processing Activities
Cooper, D. K., Sobolik, J. S., Kovacevic, J., Rock, C., Sajewski, E. T., Guest, J. L., Lopman, B. A., Jaykus, L.-A., Leon, J. S.
10.1101/2022.04.06.22273125 — Posted: 2022-04-07
Vaccine effectiveness of BNT162b2 against Omicron and Delta outcomes in adolescents
Buchan, S. A., Nguyen, L., Wilson, S. E., Kitchen, S. A., Kwong, J.
10.1101/2022.04.07.22273319 — Posted: 2022-04-07
Impact of the COVID-19 epidemic on mortality in rural coastal Kenya
Otiende, M., Nyaguara, A., Bottomley, C., Walumbe, D., Mochamah, G., Amadi, D., Nyundo, C., Kagucia, E., Etyang', A., Adetifa, I., Maitha, E., Chondo, E., Nzomo, E., Aman, R., Mwangangi, M., Amoth, P., Kasera, K., Ng'ang'a, W., Barasa, E., Tsofa, B., Mwangangi, J., Bejon, P., Agweyu, A., Williams, T., Scott, A.
10.1101/2022.04.06.22273516 — Posted: 2022-04-07
Prediction of deterioration from COVID-19 in patients in skilled nursing facilities using wearable and contact-free devices: a feasibility study
Von Preyss-Friedman, S., Emmet, L., Deckert, D., David, D. A. B., Raisanen, H., Longoria, K., Gielen, W., Frasch, M. G.
10.1101/2022.04.06.22273202 — Posted: 2022-04-07

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).